Could a short drug course keep prostate cancer at bay?
NCT ID NCT03088124
Summary
This study tested if adding a 6-month course of the drug apalutamide to standard 'watchful waiting' (active surveillance) could help men with low-risk prostate cancer. Researchers wanted to see if the drug could slow the cancer's progression and delay the need for more invasive treatments like surgery or radiation. The trial involved 93 men who were randomly assigned to receive either the drug plus surveillance or surveillance alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOW RISK PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHP Saint- Grégoire
Saint-Grégoire, 35760, France
-
CHRU Hopital Edouard Herriot
Lyon, 69437, France
-
Chu Hotel Dieu
Nantes, France
-
Chu Pontchaillou
Rennes, France
-
Chu Saint Etienne
Saint-Etienne, 42055, France
-
Chu Tenon
Paris, France
-
Chu de Nice
Nice, France
-
Clinique Beau Soleil
Montpellier, 34070, France
-
Clinique La Croix Du Sud
Quint-Fonsegrives, France
-
Hia Sainte Anne
Toulon, France
-
Hôpital de Cannes
Cannes, 06400, France
-
Institut Mutualiste Montsouris
Paris, 75014, France
-
Institut Paoli Calmettes
Marseille, Bouches du Rhône, 13009, France
Conditions
Explore the condition pages connected to this study.